TY - JOUR T1 - Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects JF - Journal of Nuclear Medicine JO - J Nucl Med DO - 10.2967/jnumed.120.251512 SP - jnumed.120.251512 AU - Sonya Youngju Park AU - Ashwin Singh Parihar AU - Lisa Bodei AU - Thomas A. Hope AU - Nadine Mallak AU - Corina Millo AU - Kalpna Prasad AU - Don Wilson AU - Katherine Zukotynski AU - Erik Mittra Y1 - 2021/07/01 UR - http://jnm.snmjournals.org/content/early/2021/07/22/jnumed.120.251512.abstract N2 - A new era of precision diagnostics and therapy for patients with neuroendocrine neoplasms began with the approval of somatostatin receptor (SSTR) radiopharmaceuticals for positron emission tomography (PET) imaging followed by peptide receptor radionuclide therapy (PRRT). With the transition from SSTR-based gamma scintigraphy to PET, the higher sensitivity of the latter raised questions regarding the direct application of the planar scintigraphy-based Krenning score for PRRT eligibility. Also, to date, the role of SSTR-PET in response assessment and predicting outcome remains under evaluation. In this comprehensive review article, we discuss the current role of SSTR-PET in all aspects of neuroendocrine neoplasms including its relation to conventional imaging, selection of patients for PRRT, and the current understanding of SSTR-PET based response assessment. We also provide a standardized reporting template for SSTR-PET with a brief discussion. ER -